Carroll D. et al. (2014)
Child and Adolescent Psychiatric Clinics of North America
January, 23(1), pp. 57-72.
Lindsay R. L. et al. (2006)
Journal of Intellectual and Developmental Disability
December, 31(4), pp. 204-209.
Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data.
American Journal of Psychiatry
161(6), pp. 1125-1127
McDougle C. J. et al. (2000)
Child and Adolescent Psychiatric Clinics of North America
January, 9(1), pp. 201-224.
Nikolov R. N. et al. (2009)
Gastrointestinal symptoms in a sample of children with pervasive developmental disorders.
Journal of Autism and Developmental Disorders
39(3), pp. 405-413
Scahill L. et al. (2006)
A prospective open trial of guanfacine in children with pervasive developmental disorders.
Journal of Child and Adolescent Psychopharmacology
16(5), pp. 589-598.
Scahill L. et al. (2012)
Journal of the American Academy of Child and Adolescent Psychiatry
51(2), pp. 136-146
Scahill L. et al. (2001)
Journal of Child and Adolescent Psychopharmacology
Winter, 11(4), pp, 377-88.
Scahill L. et al. (2017)
Journal of Child and Adolescent Psychopharmacology
March, 27(2), pp. 125-131.
Scahill L. et al. (2016)
Journal of the American Academy of Child and Adolescent Psychiatry
May, 55(5), pp. 415-423.
Vitiello B. et al. (2005)
Assessment of the integrity of study blindness in a pediatric clinical trial of risperidone.
Journal of Clinical Psychopharmacology
25(6), pp. 565-569
Vitiello B. , Wagner A. (2004)
Government initiatives in autism clinical trials.
CNS Spectrums
9(1), pp. 66-70
Perceptual and Motor Skills
December, 26(10), pp. 900-908
Williams S. K. et al. (2006)
Risperidone and adaptive behavior in children with autism.
Journal of the American Academy of Child and Adolescent Psychiatry
45(4), pp. 431-439